Sei Investments Co. Purchases 12,689 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Sei Investments Co. grew its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 35.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 48,180 shares of the company’s stock after acquiring an additional 12,689 shares during the period. Sei Investments Co. owned about 0.13% of Tarsus Pharmaceuticals worth $2,668,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in TARS. Jennison Associates LLC grew its stake in Tarsus Pharmaceuticals by 14.8% in the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock worth $138,432,000 after purchasing an additional 321,552 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Tarsus Pharmaceuticals by 0.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,146,812 shares of the company’s stock worth $63,499,000 after buying an additional 5,565 shares during the period. Geode Capital Management LLC grew its position in shares of Tarsus Pharmaceuticals by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 835,790 shares of the company’s stock worth $27,494,000 after buying an additional 62,555 shares during the period. Lord Abbett & CO. LLC increased its stake in shares of Tarsus Pharmaceuticals by 28.4% in the 3rd quarter. Lord Abbett & CO. LLC now owns 594,876 shares of the company’s stock worth $19,565,000 after acquiring an additional 131,636 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Tarsus Pharmaceuticals by 2,088.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after acquiring an additional 420,057 shares during the period. Institutional investors own 90.01% of the company’s stock.

Insider Activity at Tarsus Pharmaceuticals

In related news, insider Dianne C. Whitfield sold 2,315 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $107,161.35. Following the transaction, the insider now owns 50,751 shares of the company’s stock, valued at approximately $2,349,263.79. This trade represents a 4.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Bobak R. Azamian sold 7,131 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $330,093.99. Following the sale, the chief executive officer now directly owns 70,720 shares of the company’s stock, valued at approximately $3,273,628.80. This represents a 9.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,542 shares of company stock worth $1,581,173 over the last quarter. Company insiders own 8.25% of the company’s stock.

Tarsus Pharmaceuticals Trading Down 5.1 %

Shares of NASDAQ:TARS opened at $47.02 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28. The company has a market cap of $1.80 billion, a P/E ratio of -12.34 and a beta of 1.05. The stock’s fifty day moving average price is $49.18 and its 200-day moving average price is $46.61.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The business had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million. Sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Jefferies Financial Group raised their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Guggenheim reaffirmed a “buy” rating and set a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Barclays dropped their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. HC Wainwright restated a “buy” rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Finally, Oppenheimer upped their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $63.67.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.